233 related articles for article (PubMed ID: 19956064)
1. The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver.
Jain R; Fischer S; Serra S; Chetty R
Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):9-15. PubMed ID: 19956064
[TBL] [Abstract][Full Text] [Related]
2. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors.
Schmitt AM; Anlauf M; Rousson V; Schmid S; Kofler A; Riniker F; Bauersfeld J; Barghorn A; Probst-Hensch NM; Moch H; Heitz PU; Kloeppel G; Komminoth P; Perren A
Am J Surg Pathol; 2007 Nov; 31(11):1677-82. PubMed ID: 18059224
[TBL] [Abstract][Full Text] [Related]
3. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers.
Zhang L; Smyrk TC; Oliveira AM; Lohse CM; Zhang S; Johnson MR; Lloyd RV
Am J Surg Pathol; 2009 Oct; 33(10):1562-9. PubMed ID: 19574886
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic use of cytokeratins, CD34, and neuronal cell adhesion molecule staining in focal nodular hyperplasia and hepatic adenoma.
Ahmad I; Iyer A; Marginean CE; Yeh MM; Ferrell L; Qin L; Bifulco CB; Jain D
Hum Pathol; 2009 May; 40(5):726-34. PubMed ID: 19157505
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of CK19 and CD99 in pancreatic endocrine tumors.
Ali A; Serra S; Asa SL; Chetty R
Am J Surg Pathol; 2006 Dec; 30(12):1588-94. PubMed ID: 17122516
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratin 5/6 immunostaining in hepatobiliary and pancreatic neoplasms.
Vlasoff DM; Baschinsky DY; Frankel WL
Appl Immunohistochem Mol Morphol; 2002 Jun; 10(2):147-51. PubMed ID: 12051633
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors.
Menz A; Bauer R; Kluth M; Marie von Bargen C; Gorbokon N; Viehweger F; Lennartz M; Völkl C; Fraune C; Uhlig R; Hube-Magg C; De Wispelaere N; Minner S; Sauter G; Kind S; Simon R; Burandt E; Clauditz T; Lebok P; Jacobsen F; Steurer S; Wilczak W; Krech T; Marx AH; Bernreuther C
Hum Pathol; 2021 Sep; 115():19-36. PubMed ID: 34102222
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors.
Deshpande V; Fernandez-del Castillo C; Muzikansky A; Deshpande A; Zukerberg L; Warshaw AL; Lauwers GY
Am J Surg Pathol; 2004 Sep; 28(9):1145-53. PubMed ID: 15316313
[TBL] [Abstract][Full Text] [Related]
9. Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary Tract, and Pancreas.
Wang HL; Kim CJ; Koo J; Zhou W; Choi EK; Arcega R; Chen ZE; Wang H; Zhang L; Lin F
Arch Pathol Lab Med; 2017 Sep; 141(9):1155-1180. PubMed ID: 28854347
[TBL] [Abstract][Full Text] [Related]
10. Proposed histopathologic grading system derived from a study of KIT and CK19 expression in pancreatic endocrine neoplasm.
Zhang L; Lohse CM; Dao LN; Smyrk TC
Hum Pathol; 2011 Mar; 42(3):324-31. PubMed ID: 21190722
[TBL] [Abstract][Full Text] [Related]
11. [Diagnostic value of absent ductular reaction at hepatocellular-stromal boundaries in early stage hepatocellular carcinoma].
Zhang Q; Ma Z; Xin Q; Liu GQ; Liu BB; Gao YT; Zhang CS; Du Z
Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):924-8. PubMed ID: 24636295
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY
J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
[TBL] [Abstract][Full Text] [Related]
13. Expression of cytokeratin 19 in human hepatocellular carcinoma cell lines.
Wu F; Nishioka M; Fujita J; Murota M; Ohtsuki Y; Ishida T; Kuriyama S
Int J Oncol; 2002 Jan; 20(1):31-7. PubMed ID: 11743639
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical profiling of cytokeratin expression by endometrial stroma sarcoma.
Adegboyega PA; Qiu S
Hum Pathol; 2008 Oct; 39(10):1459-64. PubMed ID: 18619644
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers.
La Rosa S; Adsay V; Albarello L; Asioli S; Casnedi S; Franzi F; Marando A; Notohara K; Sessa F; Vanoli A; Zhang L; Capella C
Am J Surg Pathol; 2012 Dec; 36(12):1782-95. PubMed ID: 23026929
[TBL] [Abstract][Full Text] [Related]
16. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].
Yang QX; Shao CK; Feng ZY; Huang BQ; Han AJ; Xiong M; Zhao WL; Wu TT
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):678-81. PubMed ID: 15958307
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms.
Mounajjed T; Zhang L; Wu TT
Hum Pathol; 2013 Apr; 44(4):542-50. PubMed ID: 23079207
[TBL] [Abstract][Full Text] [Related]
18. Progenitor-derived hepatocellular carcinoma model in the rat.
Andersen JB; Loi R; Perra A; Factor VM; Ledda-Columbano GM; Columbano A; Thorgeirsson SS
Hepatology; 2010 Apr; 51(4):1401-9. PubMed ID: 20054870
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors.
Cai YC; Banner B; Glickman J; Odze RD
Hum Pathol; 2001 Oct; 32(10):1087-93. PubMed ID: 11679943
[TBL] [Abstract][Full Text] [Related]
20. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
